WooGene B&G Co., Ltd (KOSDAQ:018620)

South Korea · Delayed Price · Currency is KRW

2,830.00

+340.00 (13.65%)

At close: Jul 9, 2026

-30.76% (1Y)

Market Cap	21.25B -26.1%
Revenue (ttm)	54.75B +1.5%
Net Income	-2.14B
EPS	-309.98
Shares Out	6.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,800
Open	2,470.00
Previous Close	2,490.00
Day's Range	2,355.00 - 2,860.00
52-Week Range	2,120.00 - 4,358.33
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About WooGene B&G

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Hw... [Read more]

Industry Pharmaceutical Preparations

Founded 1977

Employees 99

Stock Exchange KOSDAQ

Ticker Symbol 018620

Full Company Profile

Financial Performance

In 2025, WooGene B&G's revenue was 54.76 billion, a decrease of -1.65% compared to the previous year's 55.68 billion. Losses were -1.77 billion, -66.03% less than in 2024.

Financial Statements